Mercurio Biotec

Mercurio Biotec is a biotechnology company dedicated to the discovery and development of small molecule therapeutics for neurodegenerative diseases. Spun out from the University of Cambridge, the company utilizes a proprietary drug discovery platform that applies chemical kinetics and rational design to target protein aggregation. Their approach focuses on identifying compounds that can specifically inhibit the formation of toxic oligomers and aggregates of proteins such as amyloid-beta and alpha-synuclein. By addressing the fundamental molecular mechanisms of proteopathies, Mercurio Biotec aims to develop disease-modifying treatments for conditions like Alzheimer's and Parkinson's diseases. The company's methodology represents a shift from traditional screening toward a more predictive, physics-based drug discovery process.